Response to immune checkpoint blockade in mesenchymal tumors is poorly characterized, but immunogenomic dissection of these cancers could inform immunotherapy mediators. We identified a treatment-naive patient who has metastatic uterine leiomyosarcoma and has experienced complete tumor remission for >2 years on anti-PD-1 (pembrolizumab) monotherapy. We analyzed the primary tumor, the sole treatment-resistant metastasis, and germline tissue to explore mechanisms of immunotherapy sensitivity and resistance. Both tumors stained diffusely for PD-L2 and showed sparse PD-L1 staining. PD-1 + cell infiltration significantly decreased in the resistant tumor (p = 0.039). Genomically, the treatment-resistant tumor uniquely harbored biallelic PTEN loss and had reduced expression of two neoantigens that demonstrated strong immunoreactivity with patient T cells in vitro, suggesting long-lasting immunological memory. In this near-complete response to PD-1 blockade in a mesenchymal tumor, we identified PTEN mutations and reduced expression of genes encoding neoantigens as potential mediators of resistance to immune checkpoint therapy.
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In Brief
George et al. report an exceptional responder to anti-PD-1 monotherapy in uterine leiomyosarcoma and propose mediators of treatment sensitivity and resistance. Neoantigen-directed immunoreactivity was associated with sensitivity to anti-PD-1 monotherapy, whereas resistance was associated with reduction in neoantigen expression consistent with immune evasion, and biallelic PTEN loss was associated with induction of an immunosuppressive microenvironment.
INTRODUCTION
Immune checkpoint blockade therapies, including monoclonal antibodies targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), yield durable clinical benefit in multiple tumor types (Sharma and Allison, 2015) , but response in some cancers, including mesenchymal tumors (Maki et al., 2013) , is rare. Developing predictive biomarkers of clinical benefit from immune checkpoint therapy is an ongoing challenge and could help identify patients with immune-checkpoint-responsive disease in largely immunotherapy-resistant tumor types.
Immunohistochemical staining for PD-1 ligands (PD-L1 and PD-L2) has positive prognostic value for response, but patients with PD-L1-negative tumors can still respond (Philips and Atkins, 2015) . In genomic analyses of pre-treatment tumors from immune-checkpoint-treated patients in non-small-cell lung cancer (NSCLC) and melanoma, both the total tumor burden of nonsynonymous mutations and the burden of tumor-specific immunogenic peptides generated from these mutations (neoantigens) are associated with patient benefit (McGranahan et al., 2016; Rizvi et al., 2015; Snyder et al., 2014; Van Allen et al., 2015) , although identification of the specific neoantigens mediating a strong anti-tumor response occurs in only a subset of cases (Rizvi et al., 2015; Snyder et al., 2014; van Rooij et al., 2013) . Certain tumor-immune microenvironment gene expression signatures developed from whole-transcriptome RNA sequencing (RNA-seq) on pre-treatment patient tumors also correlate with response Van Allen et al., 2015) . However, all of these factors imperfectly stratify responders and nonresponders prospectively, and additional studies in independent patient cohorts are needed.
Furthermore, acquired tumor-resistance mechanisms important in determining overall patient benefit have yet to be deeply explored. In case reports and case series, genetic alterations that delete genes encoding tumor-specific neoantigens, disrupt neoantigen presentation on major histocompatibility (MHC) class I alleles, or interfere with downstream interferon-g signaling have been associated with acquired resistance to cancer immunotherapies (Anagnostou et al., 2016; Tran et al., 2016; Verdegaal et al., 2016; Zaretsky et al., 2016) . In the preclinical space, loss of the tumor suppressor PTEN in melanoma models leads to immunoresistance via induction of VEGF and other immunosuppressive cytokines (Peng et al., 2016) , and Pten-null prostate tumors similarly suppress anti-tumor immune activity by activating the Jak2-Stat3 pathway (Toso et al., 2014) . Thus, preclinical and clinical studies suggest that tumor immune evasion via alteration of antigen-presentation machinery, loss of neoantigens, and disruption of immune-related signaling are all potential mechanisms of acquired resistance to cancer immunotherapies.
Analysis of immune checkpoint blockade response and resistance mediators has predominantly focused on tumor types with established clinical benefit to these agents, such as melanoma and NSCLC. In this study, we report a case of a treatmentnaive patient who has uterine leiomyosarcoma and has received anti-PD-1 monotherapy (pembrolizumab) for metastatic disease and experienced complete disease remission after resection of one treatment-resistant tumor. Sarcoma generally harbors few targetable genetic alterations (Barretina et al., 2010) , and although the first reported results on anti-CTLA-4 therapy in synovial sarcoma have been disappointing (Maki et al., 2013) , multiple clinical trials are currently exploring whether anti-PD-1 or anti-PD-L1 agents could be more promising (e.g., ClinicalTrials.gov: NCT02609984). We hypothesized that a combination of tumorintrinsic genomic alterations and changes in neoantigen-immunemicroenvironment interactions mediate response and selective resistance in this case. Thus, we analyzed immunohistochemistry, RNA-seq, and whole-exome sequencing (WES) to examine this patient's changing tumor-immune dynamics over time.
RESULTS

Clinical Course and Immunohistochemistry
A treatment-naive woman with uterine leiomyosarcoma was enrolled in a multi-disease phase II study of pembrolizumab monotherapy (10 mg/kg every 2 weeks; ClinicalTrials.gov: NCT02054806) ( Figure 1A ; Supplemental Information). After four doses of pembrolizumab, marked tumor regression was observed at numerous locations, and a single tumor showed continuous, albeit slowed, growth ( Figure 1B) ; after 9 months of treatment, this single tumor was removed. More than 2 years after resection of the sole treatment-resistant metastasis, the patient remains disease free on anti-PD-1 monotherapy.
The pre-treatment tumor stained weakly for PD-L1 in infiltrating mast cells (<5% of overall cellularity) and demonstrated diffuse cytoplasmic staining for PD-L2, with about 25% infiltration of PD-1 + cells ( Figure 1C ). Patterns of PD-L1 and PD-L2 staining persisted in the treatment-resistant tumor, but PD-1 positivity diminished significantly to <1% of overall cellularity (p = 0.039; Student's t test; Figures 1C and 1D) . Thus, WES and RNA-seq were pursued on pre-treatment and treatmentresistant tumors, along with WES on whole blood for germline comparison, for the assessment of genomic explanations for the diminished PD-1 + cell infiltration and associated treatment resistance, as well as exploration of genomic features associated with otherwise exceptional sensitivity to anti-PD-1 therapy in this patient (Figure 2A ).
Genomic Features of the Pre-treatment and Treatment-Resistant Tumors
Pre-treatment and treatment-resistant tumors had modest overall mutational loads (50 and 54 nonsynonymous mutations per exome, respectively; Figure 2B ; Tables S1A-S1C). No mutations conferring microsatellite instability or DNA-repair defects were detected, and no events were observed in JAK1, JAK2, JAK3, or B2M (encoding b2-microglobulin), despite adequate sequencing coverage to detect these events (Table S1D) . Phylogenetic analysis of both tumors for events in genes implicated in oncogenesis (Brastianos et al., 2015; Futreal et al., 2004 ) revealed a shared clonal nonsense mutation in TP53 (S166*; Figures 2C and 2D ), a focal amplification containing the oncogene MYC in chromosome 8q, and a heterozygous large deletion containing the tumor suppressor PTEN in chromosome 10q ( Figure 2E ). Additional somatic alterations and copy-number events (Table S1B; Figure S1 ) were of uncertain clinical significance.
Most mutations (n = 38) were shared between the pre-treatment and treatment-resistant tumors, although 12 nonsynonymous mutations were lost from the primary tumor (not seen in the treatment-resistant tumor), and 16 (all missense) were exclusive to the resistant tumor ( Figure 2D ; Tables S1B and S1C). Of these 16, the only nonsynonymous alteration in a gene previously associated with oncogenic signaling (Brastianos et al., 2015; Futreal et al., 2004 ) was a clonal missense mutation in PTEN, and there was evidence of heterozygous loss of the wild-type copy (81 variant reads out of 101 total reads; Figure 2C ). This alteration occurred within a 3D hotspot (Gao et al., 2017) in the tyrosine phosphatase domain of PTEN ( Figure 2C ) at the same locus as mutations observed in glioblastoma (Brennan et al., 2013) and colorectal cancer (Giannakis et al., 2016) , suggesting a functional role. It was not detected in the pre-treatment tumor despite 165 reads at this locus ( Figure 2C ). Although differences in the degree of stromal admixture from nearby normal tissue between the two tumor samples precluded drawing strong conclusions about tumor-specific gene expression alterations, we observed an increase in VEGFA expression in the treatment-resistant tumor (353-1,103 transcripts per million [TPM]; Table S1E ), consistent with a previously described role of PTEN loss in immune resistance in a murine model (Peng et al., 2016 ; Figure S2 ). Transcripts encoding all three human leukocyte antigen (HLA) alleles and b2-microglobulin were expressed at high levels in both tumor samples ( Figure S2 ).
Immune Gene Expression by MYC and PTEN CopyNumber Status in Mesenchymal Tumors
To further investigate possible phenotypic consequences of MYC amplification and PTEN loss in this patient, we drew on matched mutation, copy-number, and RNA-seq data from 241 untreated primary sarcomas available through The Cancer Genome Atlas (TCGA). Compared with tumors that were wildtype and copy-number neutral at the PTEN locus on chromosome 10q23.1, sarcomas that harbored both heterozygous deletion and oncogenic mutation of PTEN-similar to the genotype observed in this patient-had significantly higher levels of STAT3 expression, consistent with activation of the Jak2-Stat3 pathway in the Pten-null state (Toso et al., 2014 ; p < 0.005, Student's t test), whereas tumors with either mutation of PTEN or copy-number loss over chromosome 10q23.1, but not both, did not differ significantly from the wild-type ( Figure 2F ). In addition, tumors with biallelic PTEN loss had significantly lower levels of mRNA expression of PDCD1, CD8A, IFNG, PRF1, and GZMA than PTEN-wild-type tumors (p < 0.05 for all; Figure 2F ). Tumors harboring high MYC amplifications trended toward increased mRNA expression of MYC (p = 0.06) but did not differ in expression of any of the previously mentioned immune genes ( Figure 2F ).
Predicted Neoantigen Presentation in Pre-treatment and Treatment-Resistant Tumors
To identify tumor-specific peptides that mediate immune recognition of malignant cells in the context of immune checkpoint therapy, we predicted neoantigens from WES with in silico techniques (Hoof et al., 2009; Shukla et al., 2015; Van Allen et al., 2015) . As observed with mutational loads, neoantigen loads were moderate in both pre-treatment and treatment-resistant tumors (82 and 107, respectively; Figures 2B and 3A; Table S1F ). None of the predicted neoantigens was previously described as clinically T cell reactive (Fritsch et al., 2014; Robbins et al., 2013; Snyder et al., 2014; van Rooij et al., 2013; Verdegaal et al., 2016; Walter et al., 2012) , nor were they seen in HLA-matched responders to immune checkpoint therapy See also Figure S1 , Figure S2 , and Table S2 . Rizvi et al., 2015; Snyder et al., 2014; Van Allen et al., 2015 ; Table S2 ). Thus, we prioritized predicted neoantigens by using matched gene expression (RNA-seq) data (Figure 3A ; Table S1F ). Four putative neoantigens were predicted to be unique to the pre-treatment sample, but none of these occurred in expressed genes. Two predicted neoantigens derived from clonal somatic mutations in MB21D2 and QKI were expressed at lower levels in the resistant sample than in the pre-treatment sample ( Figures 3A-3C ).
In Vitro Evaluation of Neoantigen Recognition by Patient-Derived T Cells
To evaluate the immunogenicity of these neoantigens, we incubated peripheral-blood mononuclear cells (PBMCs) obtained from the patient after resection of the treatment-resistant tumor in vitro with neoantigens of interest from MB21D2 and QKI. Five other neoantigens that demonstrated more constant expression throughout the clinical course or were present only in the treatment-resistant setting, and thus not expected to be involved in mediating treatment response, were also evaluated ( Figure 3B ; Figure S3 ; Table S1G ). In these experiments, patient CD8 + T cells were analyzed for interferon-g release after exposure to tumor-specific peptides or wild-type peptide analogs ( Figure S4 ; Figures 4A and 4B) . Secretion of interferon-g was substantially higher after incubation with tumor-specific peptides than with wild-type peptides, and significant differences were noted for neoantigens in QKI and MB21D2 (p = 0.004 and p = 0.05, respectively, Student's t test; Figure 4C ). In addition, patient CD8 peptides than did CD8 + T cells from an unrelated healthy donor, and again the most drastic differences were seen in QKI and MB21D2 ( Figure 4D ). Thus, circulating T cells were able to recognize tumor-specific antigens months after surgical removal of metastatic disease, suggesting involvement of immunological memory in durable responses to cancer immunotherapy, whereas acquired resistance to cancer immunotherapies could occur via decreased expression of genes encoding immunogenic clonal tumor-specific mutations.
DISCUSSION
This report of a chemotherapy-naive patient who has rapidly progressive metastatic uterine leiomyosarcoma and has had an exceptional clinical response to pembrolizumab supports the need for biologically comprehensive investigation of immune checkpoint inhibitors in sarcoma. Oncogenic alterations in this patient's cancer included MYC amplification and TP53 loss-offunction mutations in both tumors; meanwhile, biallelic PTEN loss and changes in neoantigen presentation exclusive to the treatment-resistant tumor could have contributed to acquired immune resistance.
In melanoma cell lines, PTEN loss increases production of immunosuppressive cytokines (especially VEGF), which decrease cytolytic activity and T cell infiltration in the tumor microenvironment in a PD-L1-independent manner (Peng et al., 2016) . In clinical melanoma samples, negative PTEN immunohistochemical staining is associated with reduced efficacy of adoptive cell transfer and anti-PD-1 therapies (Peng et al., 2016) . Pten-deficient prostate tumors similarly induce an immunosuppressive tumor microenvironment by upregulating PTPN11 and inducing activity of the Jak2-Stat3 pathway (Toso et al., 2014) , but genetic alterations in PTEN have not yet been linked to intrinsic or acquired resistance to immune checkpoint therapies in melanoma or NSCLC (Rizvi and Chan, 2016).
One major role of JAK-STAT signaling is controlling the interferon-g response, which is commonly disrupted in melanoma tumors intrinsically resistant to immune checkpoint therapy targeting CTLA-4 (Gao et al., 2016) . Our observations of increased VEGFA expression accompanied by reduced PD-1 + T cell infiltration in a treatment-resistant mesenchymal tumor with biallelic PTEN loss, as well as increased STAT3 expression in untreated sarcomas with similar PTEN genotypes, tie together these preclinical and clinical findings in support of a PTEN-mediated mechanism of immune resistance to anti-PD-1 therapy in this patient. These findings suggest that the addition of JAK-STAT or VEGF inhibitors in clinical cases of PTEN-mediated acquired resistance to immune checkpoint monotherapy could help further control tumor growth (Peng et al., 2016; Toso et al., 2014) . We additionally identified two neoantigens with lower expression in the treatment-resistant tumor than in the pre-treatment tumor and high patient T cell reactivity in vitro, indicating that a subset of neoantigens encoded by tumor-specific mutations were capable of stimulating a T-cell-mediated anti-tumor response, and their reduced expression in the treatment-resistant tumor could have contributed to immune escape. Other patient-specific neoantigens also stimulated T cell effector cytokine release, although not significantly more than non-mutated normal peptides, and whether an effective cytotoxic T cell response, presumably induced by PD-1 blockade, relies on the presence of a small number of highly immunogenic tumor antigens or a large array of moderately reactive peptides deserves further study.
Prior studies in patients treated with immune checkpoint therapy have shown that disruptions in genes involved in neoantigen presentation are key to tumor immune evasion. For example, loss of the expression of MHC class I molecules necessary for neoantigen presentation via frameshift deletion of b2-microglobulin or deletion of HLA alleles (Tran et al., 2016) is associated with acquired resistance to cancer immunotherapies, as is the loss of neoantigens themselves via DNA-level loss-of-heterozygosity events that eliminate neoantigen-producing mutations (Anagnostou et al., 2016; Verdegaal et al., 2016) . By combining whole-exome-based mutation calls with RNA-seq, this study adds the loss of neoantigens via reduced expression of mutated genes as an additional mechanism contributing to acquired resistance to immune checkpoint therapy.
In summary, immunohistochemical, whole-exome, and wholetranscriptome analyses of pre-treatment and treatment-resistant tumors from one patient have identified PTEN loss and changes in neoantigen expression as potential clinical mechanisms of acquired resistance to immune checkpoint therapy, although further experimental work in mesenchymal tumors is needed. Prospective integrated assessment of large immunotherapy-treated cohorts in tumor types not typically considered responsive to immune checkpoint blockade could further inform recurrent features associated with response and resistance.
EXPERIMENTAL PROCEDURES Patient History and Oversight
A previously healthy 48-year-old woman developed metastatic disease 3 months after primary tumor resection of uterine leiomyosarcoma and was enrolled in a multi-disease phase II study of pembrolizumab monotherapy (10 mg/kg every 2 weeks; ClinicalTrials.gov: NCT02054806). She received no adjuvant systemic or radiation therapies prior to pembrolizumab. After four doses of pembrolizumab over 2 months, marked tumor regression was observed at a large right retroperitoneal subhepatic site and numerous other locations, whereas a peritoneal tumor in the mesentery of the small bowel continued to grow, albeit at a slower rate. After 9 months of treatment, the resistant lesion and responding sites were resected. Pathology of the subhepatic, pembrolizumab-responsive tumor site demonstrated dense and collagenous tissue with foreign body giant cell reaction, granuloma, and hemosiderin-laden macrophages. The treatment-resistant mesenteric tumor demonstrated a 9.0 cm myxoid leiomyosarcoma involving the bowel wall, which was highly mitotic (117 cells/10 high-power fields) with necrosis (up to 20% tumor volume) and tissue hemorrhage. No tumor tissue remained for sampling in the treatment-responsive lesion, but a sample from the treatment-resistant tumor was taken for genomic comparison with the primary uterine tumor and germline blood. The clinical trial of pembrolizumab was sponsored by Merck Sharp & Dohme and approved by the institutional review board of the Dana-Farber/Harvard Cancer Center. The patient provided written informed consent for molecular profiling (Dana-Farber Cancer Institute protocol no. 11-104).
WES and Whole-Transcriptome Sequencing WES and whole-transcriptome sequencing and quality control of tumor and germline samples were performed as previously described Van Allen et al., 2014) . Tumor-specific somatic point mutations, small insertions and deletions (indels), copy-number alterations, and neoantigens were identified by standard genomic analysis pipelines . Mutational clonality (the presence of a mutation in all sampled tumor cells versus a subclonal tumor population), tumor purity, and tumor ploidy were assessed with ABSOLUTE (Carter et al., 2012) and used as inputs for phylogenetic analyses (Stachler et al., 2015) . For the purposes of neoantigen prediction, all six four-digit patient HLA alleles were inferred from germline WES with Polysolver . All tumor-specific 9-and 10-aminoacid peptides generated by nonsynonymous tumor-specific somatic point mutations and small indels were stored in a FASTA file and then assessed for strength of binding to each of the patient's six HLA alleles with NetMHCpan-2.4 (Hoof et al., 2009; Nielsen et al., 2007) . Any 9-or 10-amino-acid peptide with predicted binding affinity to any HLA allele with IC 50 % 500 nM was considered a neoantigen, such that one nonsynonymous mutation could theoretically generate many neoantigens. HLA binding affinity to tumor-specific neoantigens was further confirmed with NetMHCpan-3.0 (Nielsen and Andreatta, 2016) . A neoantigen was considered expressed if gene-level TPM exceeded 1 according to RNA-Seq by Expectation Maximization (RSEM; Li and Dewey, 2011) .
TCGA Analyses
Whole-exome mutation annotation files and whole-transcriptome RNA-seq gene expression files for the TCGA sarcoma cohort were downloaded from Firebrowse (data version 2016_01_28). RNA-seq from matched normal tissue was excluded. Copy-number loss, gain, and amplification and oncogenic alterations in MYC and PTEN were defined in accordance with TCGA standards (http://firebrowse.org,http://www.cbioportal.org; Cerami et al., 2012; Gao et al., 2013) .
Neoantigen-Reactivity Experiments
PBMCs were obtained with the patient's consent after resection of the treatment-resistant metastatic lesion and were evaluated for reactivity to seven synthetic in silico predicted neoantigens and their wild-type analogs according to standard protocols (Lin et al., 2009; Maeda et al., 2014; Rizvi et al., 2015) . Tumor-specific and wild-type peptides were synthesized by GenScript. In brief, healthy donor or patient-derived PBMCs were stimulated with 10 mg/mL of mutant peptides for 10 or 12 days in the presence of IL-2 and IL-15. Cells were washed and then re-stimulated with monocyte-derived dendritic cells pulsed with the same concentration of either mutant or wild-type peptides for 24 hr or PMA and ionomycin for 6 hr. A protein transport inhibitor cocktail (Golgi stop) was added in the last 5 hr of culture. Cells were acquired by fluorescence-activated cell sorting on a BD LSRFortessa (BD Biosciences) prior to staining for interferon-g. Data were analyzed with FlowJo software (Tree Star).
Statistical Analysis
All statistical analyses were done with R version 3.2.3. Student's t tests with unequal variances were used for all comparisons of continuous variables between groups. All tests were two-tailed with an alpha level of 0.05.
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